FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

JUBLPHARMA Consensus Forecast

No. of reports in last year
4
No. of analysts
3
Average Consensus Forecast
791.75
Consensus Potential
6.12%

JUBLPHARMA Price Target Potential

BrokerageTargetPotential
Prabhudas Lilladher75211.08%
Nirmal Bang90926.44%
ICICIdirect.com106036.92%

JUBLPHARMA Targets in FrontPage Forums

6 Users have submitted 6 trade ideas of Rs. 939,700 for JUBLPHARMA
100% Bullish
0% Bearish
See buy or sell ideas on FrontPage Forums >>

JUBLPHARMA Ratings

Long term JUBLPHARMA rating by FrontPage users
4.3/5 (4 Ratings)

4 JUBLPHARMA share price target reports by brokerages below. See what is analyst's view on JUBLPHARMA share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
  1. Home
  2. JUBLPHARMA Forum
  3. JUBLPHARMA Price Target

JUBLPHARMA Share Price Target

JUBLPHARMA Share Price Target - Broker Reports - 2020

5-Nov-20
Price @ Call: 700.28
Target: 752
ACCUMULATE
5-Nov-20
Price @ Call: 706.7
Target: 909
BUY
7-Sep-20
Price @ Call: 785.87
Target: 446
SELL
7-Sep-20
Price @ Call: 785.87
Target: 1060
BUY
1-Feb-20
Price @ Call: 558.61
Target: 792
BUY
In the current quarter, the Pharma business reported an adjusted EBITDA of Rs4,110mn, while LSI business EBTIDA stood at Rs1,000 mn. The company has filed the composite Scheme of Arrangement with exchanges and is awaiting response. Once NOC is received from exchanges the company will file it with the National Company Law Tribunal (NCLT) for its approval. Post the scheme becoming effective, the Life Science Ingredients business will stand demerged into the resulting entity, which will be listed on NSE and BSE with a mirror shareholding of JLL. We have maintained our financial estimates on JLS for FY20, FY21 and FY22. We have maintained a target P/E multiple of 12x to arrive at a target price (TP) of Rs792.
... Read more
31-Jan-20
Price @ Call: 597.07
Target: 488
REDUCE
JUBILANT guided for favourable outcome of legal issues in Ruby-fill, new capacity in CDMO and FDA resolution of regulatory issues which may help in back-ended revenue growth in FY22E. The company however maintained heavy capex in FY21E. In our SOTP valuation, we increased EV/EBITDA of pharma business to 5.5x (from 5x) of FY22E while same for LSI maintained at 3x for commoditized LSI business. This has derived new TP of Rs488 (from Rs433). We maintain Reduce.
... Read more

JUBLPHARMA Share Price Target - Broker Reports - 2019

29-Oct-19
Price @ Call: 542.7
Target: 792
BUY
We have revised our financial estimates on JLS for FY20 and FY21 to account for the revised prices in the commodity chemicals business. We have also made minor changes in our costs related assumptions. We have rolled over the valuation to September FY22 with a target P/E multiple of 12x to arrive at a target price (TP) of Rs792 (from Rs834 earlier).
... Read more
25-Oct-19
Price @ Call: 566.85
Target: 433
REDUCE
JUBILANT raised US$200m debt and prepaid US$135m FCCB from IFC Washington. Its net debt reduced by Rs1.49bn in Q2FY20. Management has proposed demerger of Pharma and LSI business to unlock value of both the businesses, though shareholding to reflect mirror image. It guided for nine months to complete the process with approval from NCLT. Management plans to remain in old tax regime with guidance of effective annual tax outflow of 25% while reported tax liability to be 29-30%. We maintain ‘Reduce’ recommendation and retain TP at Rs433.
... Read more
29-Jul-19
Price @ Call: 445.85
Target: 845
BUY
Concerns overplayed We maintain BUY on JUBILANT following an 8/12% beat on our EBITDA/PAT estimates for 1QFY20. Our TP is revised at Rs 845 (12x Jun-21E EPS) with a 5/10% cut to our FY20/21E EPS due to higher interest cost and tax rate.
... Read more
29-Jul-19
Price @ Call: 445.85
Target: 785
BUY
We revise our financial estimates on JLS for FY20 and FY21 to account for the revised prices in commodity chemicals business, ongoing impact of remediation measures on supply of API / solid dosage business and lower our estimates for Ruby fill for FY21. lower our target P/E multiple to 12x from 13x and arrive at a target price (TP) of Rs785.
... Read more
24-May-19
Price @ Call: 516.5
Target: 750
BUY
We expect the pharma business to be stable as RubyFill is gaining market share. However, considering Roorkee WL, pressure on LSI, and a higher tax rate, we have a negative view for FY20 than our earlier assumption. We expectthe improving situation for Vitamin B3 and CMO’s additional capacities(starting a second line in H2FY20, commissioning Lyo in FY20) to provide aid tothe company’s performance. Considering the recent correction in the market,we have a BUY rating, with a TP of Rs 750 (10x FY21E EPS).
... Read more
20-May-19
Price @ Call: 564.8
Target: 800
BUY
We reduce our EPS estimate by 5%/7% for FY20/21 to factor in remediation cost associated with compliance in the pharma segment, further penalties associated with non-supplies to customers, and reduced prices in LSI products. We also reduce EV/EBITDA multiple for pharma to 9x (prior: 10x) and for LSI to 5x (prior: 6x) to factor in (a) regulatory risk in the pharma segment, (b) gradual pick-up in radio-pharma, and (c) subdued outlook for the Life Science Chemical Segment. Accordingly, we roll our price target to INR800 on SOTP-based valuation. At CMP of INR595, JUBILANT trades at an attractive valuation of 6.3x FY20 EV/EBITDA and 5.7x FY21 EV/EBITDA. Maintain Buy.
... Read more
20-May-19
Price @ Call: 596.05
Target: 710
BUY
We expect specialty pharma to maintain growth momentum thanks strong growth and prospects for CDMO business. However, Official action Indicated (OAI) status to Nanjangud API facility is a likely stumbling block in the near term. Similarly, on the generics front, we expect some slowdown and costs escalation on account of warning letter to Roorkee facility. On the LSI front, despite inventory adjustment, EBITDA margins were disappointing and things are unlikely to improve in the next few quarters. In this backdrop, the performance pharma will be the main lever in the near future. We cut our EPS estimates by ~20% in both FY20 and FY21 due to these factors. We arrive at our target price of ~| 710 based on 10x FY21E EPS of Rs 70.8.
... Read more
11-Mar-19
Price @ Call: 768.5
Target: 703
REDUCE
We cut our earnings estimates by 2.2% and 3.9% in FY20E and FY21E respectively, following assumptions of lower sales growth in US formulation. We expect that negative impact of the event as well as raising new debt capital will result in compression of PE multiples. We reduce assigned EV/EBTIDA to 7.5x (from 8.5x) on FY21E in our SOTP valuations of the company. The current valuation reflects all possible positive developments in the near to medium term. With muted demand offtake in chemical biz (LSI), higher leverage and regulatory uncertainties, we downgrade our recommendation to ‘Reduce’ and lower TP to Rs703 (Rs822 earlier).
... Read more
8-Feb-19
Price @ Call: 756.71
Target: 900
BUY
6-Feb-19
Price @ Call: 740
Target: 1070
BUY
5-Feb-19
Price @ Call: 733.1
Target: 905
BUY
4-Feb-19
Price @ Call: 711.55
Target: 1050
BUY
1-Feb-19
Price @ Call: 714.77
Target: 822
ACCUMULATE
22-Jan-19
Price @ Call: 701.5
Target: 814
BUY

JUBLPHARMA Share Price Target - Broker Reports - 2018

24-Dec-18
Price @ Call: 712.89
Target: 980
BUY
5-Dec-18
Price @ Call: 818.95
Target: 965
BUY
23-Oct-18
Price @ Call: 651.25
Target: 980
BUY
23-Oct-18
Price @ Call: 651.25
Target: 945
BUY
23-Oct-18
Price @ Call: 651.25
Target: 900
BUY
22-Oct-18
Price @ Call: 672.65
Target: 723
ACCUMULATE
30-Jul-18
Price @ Call: 768.6
Target: 990
BUY
30-Jul-18
Price @ Call: 768.6
Target: 930
BUY
28-Jul-18
Price @ Call: 801.49
Target: 1020
BUY
28-Jul-18
Price @ Call: 801.49
Target: 880
ACCUMULATE
18-Jun-18
Price @ Call: 765.8
Target: 1040
BUY
10-May-18
Price @ Call: 857.8
Target: 1060
BUY
10-May-18
Price @ Call: 846.75
Target: 1080
BUY
10-May-18
Price @ Call: 846.75
Target: 1110
BUY
10-May-18
Price @ Call: 846.75
Target: 937
ACCUMULATE
18-Jan-18
Price @ Call: 921.25
Target: 1090
BUY
18-Jan-18
Price @ Call: 921.25
Target: 1110
BUY
8-Jan-18
Price @ Call: 777.6
Target: 957
BUY

JUBLPHARMA Share Price Target - Broker Reports - 2017

14-Dec-17
Price @ Call: 670.8
Target: 893
BUY
31-Oct-17
Price @ Call: 639.6
Target: 861
BUY
19-Jul-17
Price @ Call: 718
Target: 845
BUY
18-Jul-17
Price @ Call: 704
Target: 905
NEUTRAL
4-Jul-17
Price @ Call: 692
Target: 905
BUY
8-Feb-17
Price @ Call: 704
Target: 810
BUY

JUBLPHARMA Share Price Target - Broker Reports - 2016

27-May-16
Price @ Call: 343
Target: 405
BUY
28-Oct-16
Price @ Call: 649
Target: 740
ACCUMULATE
28-Oct-16
Price @ Call: 649
Target: 795
BUY
5-Oct-16
Price @ Call: 642.5
Target: 750
ACCUMULATE
3-Oct-16
Price @ Call: 653
Target: 795
BUY
31-Aug-16
Price @ Call: 538.41
Target: 635
BUY
11-Aug-16
Price @ Call: 367
Target: 405
BUY
11-Aug-16
Price @ Call: 363.5
Target: 484
BUY
5-Jul-16
Price @ Call: 320.07
Target: 484
BUY
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • JUBLPHARMA Share Price Target Today- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 3693.8
    Upside Target 2684.35
    Upside Target 1677.95
    Pivot668.5
    Downside Target 1662.1
    Downside Target 2652.65
    Downside Target 3646.25
  • JUBLPHARMA Share Price Target weekly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 3753.07
    Upside Target 2739.03
    Upside Target 1718.07
    Pivot704.03
    Downside Target 1683.07
    Downside Target 2669.03
    Downside Target 3648.07
  • JUBLPHARMA Share Price Target monthly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 31,006.83
    Upside Target 2943.42
    Upside Target 1837.83
    Pivot774.42
    Downside Target 1668.83
    Downside Target 2605.42
    Downside Target 3499.83
  • JUBLPHARMA Share Price Target today- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 3684.35
    Upside Target 2678.3
    Upside Target 1674.55
    Pivot668.5
    Downside Target 1662.45
    Downside Target 2658.7
    Downside Target 3652.65
  • JUBLPHARMA Share Price Target weekly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 3739.03
    Upside Target 2725.66
    Upside Target 1717.4
    Pivot704.03
    Downside Target 1690.66
    Downside Target 2682.4
    Downside Target 3669.03
  • JUBLPHARMA Share Price Target monthly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 3943.42
    Upside Target 2878.86
    Upside Target 1838.97
    Pivot774.42
    Downside Target 1709.86
    Downside Target 2669.97
    Downside Target 3605.42
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.
PrivacyTerms
FrontPage © 2020